58 related articles for article (PubMed ID: 21167210)
1. Interferon plus Chinese herbs are associated with higher sustained virological response than interferon alone in chronic Hepatitis C: a meta-analysis of randomised trials.
Zhao S; Liu E; Wei K; Lu S; Chu Y; Li Y; Wang Y; Huang B; Chen Y; Yang P
Antiviral Res; 2011 Feb; 89(2):156-64. PubMed ID: 21167210
[TBL] [Abstract][Full Text] [Related]
2. Meta-Analysis of Combination Therapy of Chinese Herbs Plus Interferon and Ribavirin in Patients with Chronic Hepatitis C.
Wang J; Xin S; Jin X; Cheng Y; Yan T; Qing S; Ding N; Zhao P
Med Sci Monit; 2016 May; 22():1817-26. PubMed ID: 27237628
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon plus Chinese herbal therapy is associated with a higher virological response than only peginterferon therapy in chronic hepatitis C.
Cheng D; Liu E; Li Y; Liu R; Bai L; Chen Y; Wang Y; Chu Y; Wu M; Cheng G; Zhao S
Eur J Clin Microbiol Infect Dis; 2014 Mar; 33(3):433-8. PubMed ID: 24022094
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials.
Mangia A; Leandro G; Helbling B; Renner EL; Tabone M; Sidoli L; Caronia S; Foster GR; Zeuzem S; Berg T; Di Marco V; Cino N; Andriulli A
J Hepatol; 2004 Mar; 40(3):478-83. PubMed ID: 15123363
[TBL] [Abstract][Full Text] [Related]
5. [Compound Chinese herbal medicines, Chinese herbal drugs and their active extracts for treatment of chronic hepatitis C: a systematic review and meta-analysis of randomized clinical trials].
Qin XK; Han M; Liu JP
Zhong Xi Yi Jie He Xue Bao; 2009 Oct; 7(10):913-28. PubMed ID: 19828101
[TBL] [Abstract][Full Text] [Related]
6. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
7. A decade of trials of interferon-alpha for chronic hepatitis C. A meta-regression analysis.
Tinè F; Attanasio M; Russo F; Pagliaro L
Contemp Clin Trials; 2005 Apr; 26(2):179-210. PubMed ID: 15837440
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
McHutchison JG; Shiffman ML; Cheung RC; Gordon SC; Wright TL; Pottage JC; McNair L; Ette E; Moseley S; Alam J
Antivir Ther; 2005; 10(5):635-43. PubMed ID: 16152757
[TBL] [Abstract][Full Text] [Related]
9. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
Cornberg M; Hadem J; Herrmann E; Schuppert F; Schmidt HH; Reiser M; Marschal O; Steffen M; Manns MP; Wedemeyer H
J Hepatol; 2006 Feb; 44(2):291-301. PubMed ID: 16360972
[TBL] [Abstract][Full Text] [Related]
10. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
[TBL] [Abstract][Full Text] [Related]
11. [Is chronic hepatitis C treatment as efficient in the general population as in randomised trials?].
Hatem C; Jooste V; Minello A; Evrard P; Obert B; Bresson Hadni S; Miguet JP; Faivre J; Bonithon C; Hillon P; ;
Gastroenterol Clin Biol; 2003; 27(8-9):732-7. PubMed ID: 14586246
[TBL] [Abstract][Full Text] [Related]
12. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.
Mangia A; Minerva N; Annese M; Leandro G; Villani MR; Santoro R; Carretta V; Bacca D; Giangaspero A; Bisceglia M; Ventrella F; Dell'Erba G; Andriulli A
Hepatology; 2001 Apr; 33(4):989-93. PubMed ID: 11283865
[TBL] [Abstract][Full Text] [Related]
14. [Syndrome distribution among patients with chronic hepatitis C and interventions of integrated traditional Chinese and Western medicine: study protocol].
Nie HM; Gao YQ; Chen JJ
Zhong Xi Yi Jie He Xue Bao; 2011 Apr; 9(4):365-73. PubMed ID: 21486548
[TBL] [Abstract][Full Text] [Related]
15. [Situation and prospect of TCM treatment of chronic hepatitis C].
Wang LT
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Jan; 28(1):11-2. PubMed ID: 18418960
[No Abstract] [Full Text] [Related]
16. [Higher dose of interferon treatment of chronic hepatitis C patient with primary non-response: a case report].
Liu YL; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2010 Dec; 18(12):950. PubMed ID: 21205489
[No Abstract] [Full Text] [Related]
17. Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C.
Batey RG; Bensoussan A; Fan YY; Bollipo S; Hossain MA
J Gastroenterol Hepatol; 1998 Mar; 13(3):244-7. PubMed ID: 9570235
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of traditional Chinese medicine for cooling blood and eliminating toxins and strengthening and purifying spleen in the treatment of refractory hepatitis C.
Jing FD; Ma ZG; Liu YB; Yan G
J Biol Regul Homeost Agents; 2016; 30(1):247-53. PubMed ID: 27049099
[TBL] [Abstract][Full Text] [Related]
19. The Chinese medicine Kuan-Sin-Yin improves liver function in patients with chronic hepatitis C: A randomised and placebo-controlled trial.
Liu CY; Ko PH; Yen HR; Cheng CH; Li YH; Liao ZH; Hsu CH
Complement Ther Med; 2016 Aug; 27():114-22. PubMed ID: 27515885
[TBL] [Abstract][Full Text] [Related]
20. [Uncommon adverse effects after interferon therapy in patients with hepatitis C].
Pisabarros Blanco C; Álvarez Cuenllas B; Gutiérrez Torices C; Linares Torres P; Vivas Alegre S
Gastroenterol Hepatol; 2013 Dec; 36(10):624-5. PubMed ID: 24018313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
